<DOC>
	<DOCNO>NCT02514681</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety pertuzumab , trastuzumab chemotherapy pertuzumab retreatment compare trastuzumab chemotherapy locally advance metastatic breast cancer patient previously treat pertuzumab</brief_summary>
	<brief_title>A Randomized , Open-label Phase III Trial Evaluate Efficacy Safety Pertuzumab Retreatment Previously Pertuzumab , Trastuzuamb Chemotherapy Treated Her2-Positive Metastatic Locally Advanced Metastatic Breast Cancer ( Study Perjeta Re-treatment Clinical Outcomes )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Histologically cytologically confirm invasive breast cancer 2 . A confirmed HER2positive status assess mean immunohistochemical analysis ( 3+ indicate positive status ) and/or situ hybridization ( amplification ratio &gt; 2.0 indicate positive ) institute 3 . History pertuzumab trastuzumabcontaining chemotherapy locally advance metastatic breast cancer ( 2 3 regimen previous chemotherapy regimen locally advance metastatic breast cancer ) . The late regimen enrollment dose include pertuzumab . 4 . Patients measurable and/or nonmeasurable disease accord RECIST ver1.1 . 5 . Female patient age ≥ 20 year . 6 . Left Ventricular Ejection Fraction ( LVEF ) &gt; 50 % baseline ( within 28 day enrollment ) determine either ECHO MUGA 7 . Eastern Cooperative Oncology Group performance status 0,1 2 . 8 . Life expectancy patient expect least 3 month . 9 . Signed write inform consent ( approved Institutional Review Board Independent Ethics Committee ) obtain study procedure . 1 . History chemotherapy &gt; 4 regimen locally advance metastatic disease except cancer chemotherapeutic agentfree treatment regimen ( eg , hormonal therapy alone , combination hormonal therapy trastuzumab antiHER2 therapy alone ) . 2 . Persistent Grade &gt; 3 nonhematologic toxicity accord NCICTCAE v4.0JCOG result previous therapy time enrollment . 3 . Symptomatic uncontrolled central nervous system metastasis . 4 . Multiple malignancy without history breast cancer ( within 10 year invasive breast cancer within 5 year malignancy except invasive breast cancer ) 5 . History exposure follow cumulative dos anthracyclines : doxorubicin liposomal doxorubicin &gt; 360 mg/m2 epirubicin &gt; 720 mg/m2 mitoxantrone &gt; 100 mg/m2 If 1 anthracycline use , cumulative dose must exceed equivalent 360 mg/m2 doxorubicin . 6 . Current uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) unstable angina . 7 . History CHF New York Heart Association criterion , serious cardiac arrhythmia require treatment ( exception , atrial fibrillation , paroxysmal supraventricular tachycardia ) . 8 . History myocardial infarction within 6 month enrollment . 9 . Dyspnea rest due complication advance malignancy . 10 . Inadequate organ function , determine follow laboratory result , within 28 day enrollment : Absolute neutrophil count &lt; 1,500/mm3 Platelet count &lt; 100,000/mm3 Hemoglobin &lt; 8.0 g/dL Total bilirubin &gt; 2.0 mg/dL , unless patient document Gilbert 's syndrome Aspartate aminotransferase ( AST [ SGOT ] ) alanine aminotransferase ( ALT [ SGPT ] ) &gt; 100IU /L follow exception ( If consider liver dysfunction due liver metastasis &gt; 200 IU/L , 100 &lt; , ≤200 IU/L serum albumin &lt; 2.5 g/dL ) Serum creatinine value &gt; 2.0 mg/dL 177 μmol/L 11 . Current severe uncontrolled systemic disease ( eg . Clinically significant cardiovascular , pulmonary metabolic disease , disorder wound healing , ulcer fracture ) 12 . Uncontrolled malignancyassociated hypercalcemia syndrome bisphosphonates denosumab treatment . 13 . Radiation relate grade &gt; 2 adverse event within 14 day enrollment . 14 . Major surgical procedure significant traumatic injury within 28 day enrollment anticipation need major surgery course study treatment . 15 . Pregnant woman positive pregnancy test . 16 . Nursing woman 17 . History receive investigational treatment within 28 day enrollment . 18 . Current know active infection human immunodeficiency virus , hepatitis B virus hepatitis C virus . 19 . Receipt intravenous antibiotic infection within 14 day enrollment . 20 . Current chronic daily treatment ( continuous &gt; 3 month ) corticosteroid ( dose equivalent great 10 mg/day methylprednisolone ) , exclude inhaled steroid . 21 . Known hypersensitivity pertuzumab trastuzumab without infusion reaction relate drug 22 . Assessed investigator unable unwilling comply requirement protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>